Mass spectrometry instrumentation has made strides in recent years in terms of dynamic range and sensitivity, putting researchers in a better position to use the technology to tackle the challenges of disease biomarker discovery and validation.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Change history
29 September 2008
NOTE: In the version of this article initially published, Box 1 incorrectly listed the University of California, Berkeley as one of the five Clinical Proteomic Technology Assessment for Cancer (CPTAC) groups. The University of California, San Francisco-Lawrence Berkeley National Laboratory-Buck Institute is the correct designation for this CPTAC group. This error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blow, N. Mass spectrometry and proteomics: hitting the mark. Nat Methods 5, 741–747 (2008). https://doi.org/10.1038/nmeth0808-741
Issue date:
DOI: https://doi.org/10.1038/nmeth0808-741
This article is cited by
-
Erratum: Mass spectrometry and proteomics: hitting the mark
Nature Methods (2008)
